In August 2023, the Next Generation Dx conference in Washington had a number of exceptionally worthwhile talks. Two of them will be highlighted here at Discoveries in Health Policy. A future blog will discuss the presentation of Lee Fliescher MD, prior chief medical officer at CMS, who provided insights into TCET, CED, and other CMS topics.
Today, I'd like to highlight one of several excellent talks on pharmacogenomics. This talk, by Annette Taylor MS, PhD of Labcorp, featured research by the STRIPE Collaborative Community’s Study Design Task Force , to appear soon as Patel JN et al. Her talk reviewed several major recent papers in PGx, the landmark MolDX PGx policy in 2020 for which she played an advisory role, and similar Medicare policies at Novitas/FCSO, and she reviewed selected early data from Patel.
Patel et al. evaluated 12 payor or LBM policies for their PGx coverage. As shown in the bar chart below, coverage for the 63 strong evidence drug-gene pairs assessed ranged from 2 (Cigna) to 63 (MolDX), suggesting wide disparities currently in the coverage process (Patel et al., submitted 2023). See a select bar chart below from their data. I'll cover the range of research findings in more detail when the paper appears.
|Click to Enlarge|